Editorial & Advisory Boards

Pharmacy Practice Editorial Board

David A. Holdford (associate editor) Virginia Commonwealth University (USA)

> Shalom I. Benrimoj University of Granada (Spain)

> Karen B. Farris University of Michigan (USA)

Martin Schulz Freie Universitaet Berlin and ABDA – Federal Union of German Associations of Pharmacists (Germany)

> Cassyano J. Correr Federal University of Parana (Brazil)

> Fernanda S. Tonin Federal University of Parana (Brazil)

Jonathan Penm University of Sydney (Australia)

Meagen Rosenthal University of Mississippi (USA)

Carrie M. Blanchard University of North Carolina (USA)

Sarah Dineen-Griffin University of Technology Sydney (Australia)

_

Advisory Board

Marja Airaksinen, University of Helsinki (Finland) Simon Bell, University of South Australia (Australia) Maria Cordina, University of Malta (Malta) Souheil Hallit, Holy Spirit University of Kaslik (Lebanon) Mohamed A. Hassali, University Sains Malaysia (Malaysia) James Hoehns, University of Iowa (USA) Carmel Hughes, Queen's University Belfast (UK) Ulrich Jaehde, University of Bonn (Germany) Rosemin Kassam, University of British Columbia (Canada) David Nau, Pharmacy Quality Solutions (USA) Julie A. Patterson, Virginia Commonwealth University (USA) Kimberly S. Plake, Purdue University (USA) Bandana Saini, University of Sydney (Australia) Anthony Serracino-Inglott, University of Malta (Malta) Mary Tully, University of Manchester (UK) Asim Ahmed Elnour, Al Ain University (UAE)

Make a Submission (https://www.pharmacypractice.org/index.php/pp/about/submissions)

Browse

Categories

» Pharm Pract (Granada) editorial policy (https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy)

» Simulated Patient Technique (https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech)

» Integration of community pharmacy in primary health care (https://www.pharmacypractice.org/index.php/pp/catalog/category/integration)

» Medication Adherence (https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh)

 Pharmacy
 Practice
 | e-ISSN:
 1886-3655
 p-ISSN:
 1885-642X

 (https://www.pharmacypractice.org/journal/index.php/pp/authors#a4)

CODEN: PPHRGO

Privacy Policy

eISSN: 1886-3655 (Electronic) ISSN: 1885-642X (Print) Home (https://www.pharmacypractice.org/index.php/pp/index) / Archives (https://www.pharmacypractice.org/index.php/pp/issue/archive) / Vol. 20 No. 4 (2022): Oct-Dec

ORIGINAL RESEARCH	
Impact of automated drug dispensing system on patient safety (https://www.pharmacypractice.org/index.php/pp/article/view/2744)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Majed Falah Alanazi, Majed Ibrahim Shahein, Hamad Mohammed Alsharif, Saif Mohammed Alotaibi, Abdulsalam Owaidh Alanazi, Ahmed Obaidallah Alanazi, Umar Abdolah Alharbe, Hanad S.S. Almfalh, Palanisamy Amirthalingam Ahmed Mohsen Hamdan, Vinoth Prabhu Veeramani, Shahul Hameed Pakkir Mohamed, Mostafa A. Sayed Ali Abstract ● 803 PDF Downloads 🕹 646 IDOI https://doi.org/10.18549/PharmPract.2022.4.2744 (https://doi.org/10.18549/PharmPract.2022.4.2744) I gage 1-11	ι,
Knowledge and attitude regarding coronavirus disease 2019 (COVID-19) among hospital pharmacists in Qatar (https://www.pharmacypractice.org/index.php/pp/article/view/2646) Lama Madi, Doua Alsaad, Raja Al Khawaja, Wessam El Kassem, Moza Al Hail Abstract ● 484 PDF Downloads ▲ 458 � DOI https://doi.org/10.18549/PharmPract.2022.4.2646 (https://doi.org/10.18549/PharmPract.2022.4.2646) Im Page 01-08	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Conceptualization, development, and evaluation of 'pharmaceutical product development' graduate program within pharmacy discipline (https://www.pharmacypractice.org/index.php/pp/article/view/2662)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Aliasgar Shahiwala, Sabeena Salam Abstract 👁 324 PDF Downloads 🛓 371 SDOI https://doi.org/10.18549/PharmPract.2022.4.2662 (https://doi.org/10.18549/PharmPract.2022.4.2662) I Page 01-07	
C-reactive protein point of care testing in community pharmacy: Observational study of a Northern Ireland pilot (https://www.pharmacypractice.org/index.php/pp/article/view/2711)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Katherine O'Neill, Glenda Fleming, Michael SCOTT, Gillian Plant, Sumanthra Varma Abstract ● 459 PDF Downloads	
Oncological patient management on the territory: The results of a survey in the north-west of Italy (https://www.pharmacypractice.org/index.php/pp/article/view/2716)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Francesca Baratta, Irene Pignata, Gaia Vicenzi, Lorenzo Ravetto Enri, Pietro Quaglino, Alessandro Comandone, Ada Ala, Massimiliano Icardi, Rosella Spadi, Paola Brusa Abstract 👁 348 PDF Downloads 🛓 358 3 DOI https://doi.org/10.18549/PharmPract.2022.4.2716 (https://doi.org/10.18549/PharmPract.2022.4.2716) I Page 1-9	
Characterisation of institutionalised Portuguese older adult fallers: is there a place for pharmacist intervention? A preliminary study (https://www.pharmacypractice.org/index.php/pp/article/view/2799)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Carina Ramos Ferreira, Filipa MASCARENHAS-MELO, Ana Rita Rodrigues, Maria João Reis Lima, João Páscoa Pinheiro, Claudia CHAVES, Edite Teixeira-Lemos, Victoria Bell Abstract ● 380 PDF Downloads 土 388 �DOI https://doi.org/10.18549/PharmPract.2022.4.2717 (https://doi.org/10.18549/PharmPract.2022.4.2717) III Page 1-10	

Assessing adherence to medications: Is there a difference between a subjective method and an objective method, or between using them concurrently? (https://www.pharmacypractice.org/index.php/pp/article/view/2723) Razan I. Nassar, Bandana Saini, Nathir M. Obeidat, Noor Atatreh, Iman A. Basheti Abstract @ 425 PDF Downloads 🛓 409 & DOI https://doi.org/10.18549/PharmPract.2022.4.2723 (https://doi.org/10.18549/PharmPract.2022.4.2723) I Page 1-7	
Double blind randomized controlled trial for subjects undergoing surgery receiving surgical antimicrobial prophylaxis at tertiary hospital: the clinical pharmacist's interventions (https://www.pharmacypractice.org/index.php/pp/article/view/2727) Asim Ahmed Elnour, Israa Y AI- Khidir, Habab Elkheir, Abdalla Elkhawad, Ahmed A Mohammed O, AI-Kubaissi Khalid A, Ghadah Nahar, Shahad Fayad Alrwili, Donia Ahmed Alshelaly, Amjad Saleh, Latefa khulif Aljaber, Abrar Ayad Alrashedi Abstract © 438 PDF Downloads 🛓 392 🏈 DOI https://doi.org/10.18549/PharmPract.2022.4.2727 (https://doi.org/10.18549/PharmPract.2022.4.2727) 🗐 Page 1-17	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Your clinical pharmacist can save your life, the impact of pharmacists intervention (https://www.pharmacypractice.org/index.php/pp/article/view/2729 Éva Ságiné Polics, Zsófia Romvári, Katalin Dormán, Dóra Endrei Abstract ● 465 PDF Downloads 🛓 429 & DOI https://doi.org/10.18549/PharmPract.2022.4.2729 (https://doi.org/10.18549/PharmPract.2022.4.2729) ■ Page 1-7	(https://www.pharmacypractice.org/index.php/pp/article/view/2
Evaluation of patient comprehension and quality of consumer medicine information (https://www.pharmacypractice.org/index.php/pp/article/view/2730 Supawinee Pongpunna, Kamonphat Wongtaweepkij, Thongchai Pratipanawatr, Narumol Jarernsiripornkul Abstract © 352 PDF Downloads 🛓 355 🏈 DOI https://doi.org/10.18549/PharmPract.2022.4.2730 (https://doi.org/10.18549/PharmPract.2022.4.2730)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan (https://www.pharmacypractice.org/index.php/pp/article/view/2733) Yasuaki Mino, Takafumi Naito, Junya Ohshiro, Takahiro Yamada, Junichi Kawakami Abstract 👁 386 PDF Downloads 🕹 328 🏈 DOI https://doi.org/10.18549/PharmPract.2022.4.2733 (https://doi.org/10.18549/PharmPract.2022.4.2733) 🗐 Page 1-4	(https://www.pharmacypractice.org/index.php/pp/article/view/z
The impact of telepharmacy on hypertension management in the United Arab Emirates (https://www.pharmacypractice.org/index.php/pp/article/view/2734) Osama Mohamed Ibrahim, Ahmad Z. Al Meslamani, Rana Ibrahim, Rawan Kaloush, Nadia Al Mazrouei Abstract ● 406 PDF Downloads ▲ 409 � DOI https://doi.org/10.18549/PharmPract.2022.4.2734 (https://doi.org/10.18549/PharmPract.2022.4.2734) ■ Page 1-11	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Prevalence and factors associated with potentially inappropriate medication and medication complexity for older adults in the emergency department of a secondary teaching hospital in Indonesia (https://www.pharmacypractice.org/index.php/pp/article/view/2735) Khusnul Fitri Hamidah, Mahardian Rahmadi, Farah Meutia, Prihatma Kriswidyatomo, Firman Suryadi Rahman, Zamrotul Izzah, Bambang Subakti Zulkarnain, Leopold N. Aminde, Christopher Paul Alderman, Yulistiani, Budi Suprapti Abstract © 494 PDF Downloads 🛓 475 ©DOI https://doi.org/10.18549/PharmPract.2022.4.2735 (https://doi.org/10.18549/PharmPract.2022.4.2735)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
-	

	(https://www.pharmacypractice.org/index.php/pp/article/view/2
Medications adherence and associated factors among patients with stroke in the Kingdom of Saudi Arabia	
(https://www.pharmacypractice.org/index.php/pp/article/view/2736)	
Iman A. Basheti, Shahnaz M. Ayasrah, Muayyad M. Ahmad, Hana M. Abu-Snieneh, Fuad H. Abuadas Abstract 👁 506 PDF Downloads 🛓 432 🔗 DOI https://doi.org/10.18549/PharmPract.2022.4.2736 (https://doi.org/10.18549/PharmPract.2022.4.2736) 🗐 Page 1-9	
A pseudo-customer cross-sectional study to evaluate the community pharmacist's management of migraine in pregnant women (https://www.pharmacypractice.org/index.php/pp/article/view/2739)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Khalid Al Kubaisi, Sanah Hasan, Nageeb AbdulGalil Hassan, Asim Ahmed elnour Abstract ● 363 PDF Downloads 🛓 349 �DOI https://doi.org/10.18549/PharmPract.2022.4.2739 (https://doi.org/10.18549/PharmPract.2022.4.2739) III Page 1-9	
	DF PDF
Assessment of knowledge and counseling practice of warfarin among pharmacists in UAE: A cross-sectional study (https://www.pharmacypractice.org/index.php/pp/article/view/2741)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Ayah Moath Alkherat, Doaa Kamal Alkhalidi Abstract ● 417 PDF Downloads 🛃 382 �DOI https://doi.org/10.18549/PharmPract.2022.4.2741 (https://doi.org/10.18549/PharmPract.2022.4.2741) III Page 1-7	
Computational medicinal chemistry role in clinical pharmacy education: Ingavirin for coronavirus disease 2019 (COVID-19) discovery model (https://www.pharmacypractice.org/index.php/pp/article/view/2746)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Loai M Saadah, Ghina'a I Abu Deiab, Qosay Al-Balas, Iman A Basheti Abstract ● 424 PDF Downloads 🛓 375 �DOI https://doi.org/10.18549/PharmPract.2022.4.2746 (https://doi.org/10.18549/PharmPract.2022.4.2746) III Page 1-7	
Promoting rational herb-drug use through pharmacy-led advice and home visits in NCD patients (https://www.pharmacypractice.org/index.php/pp/article/view/2747)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Chanuttha Ploylearmsang, Juntip Kanjanasilp, Juthamas Tadtiyanant, Piyaporn Sisala Abstract ● 329 PDF Downloads よ 358 � DOI https://doi.org/10.18549/PharmPract.2022.4.2747 (https://doi.org/10.18549/PharmPract.2022.4.2747) I Page 1-10	
Le raye i lo	
Supporting and inhibiting factors of accepting COVID-19 booster vaccination in the elderly in north Jakarta, Indonesia (https://www.pharmacypractice.org/index.php/pp/article/view/2748)	(https://www.pharmacypractice.org/index.php/pp/article/view/2
Fonny Cokro, Sharon, Hadiyanto	
Abstract 👁 453 PDF Downloads 🛓 427 & DOI https://doi.org/10.18549/PharmPract.2022.4.2748 (https://doi.org/10.18549/PharmPract.2022.4.2748) I Page 1-9	
A questionnaire based survey among pharmacy practitioners to evaluate the level of knowledge and confidence towards antimicrobial stewardship (https://www.pharmacypractice.org/index.php/pp/article/view/2757)	(https://www.pharmacypractice.org/index.php/pp/article/view/z
Syed Wasif Gillani, Manar Khalil Saeed Shahwan, Doreen E. Szollosi Abstract ● 457 PDF Downloads 土 402 �DOI https://doi.org/10.18549/PharmPract.2022.4.2757 (https://doi.org/10.18549/PharmPract.2022.4.2757) 国 Page 1-9	

Categories

» Pharm Pract (Granada) editorial policy (https://www.pharmacypractice.org/index.php/pp/catalog/category/EditPolicy)

» Simulated Patient Technique (https://www.pharmacypractice.org/index.php/pp/catalog/category/SimPatTech)

» Integration of community pharmacy in primary health care (https://www.pharmacypractice.org/index.php/pp/catalog/category/integration)

» Medication Adherence (https://www.pharmacypractice.org/index.php/pp/catalog/category/medadh)

Pharmacy Practice e-ISSN: 1886-3655 -	p-ISSN: 1885-642X	-	CODEN: PPHRGO	Privacy Policy
(https://www.pharmacypractice.org/journal/index.php/p	p/authors#a4)			

eISSN: 1886-3655 (Electronic) ISSN: 1885-642X (Print)

OJS Hosting, Support, and Customization by: OpenJournalSystems.com (https://openjournalsystems.com/ojs-hosting)

https://doi.org/10.18549/PharmPract.2022.4.2735

Original Research

Prevalence and factors associated with potentially inappropriate medication and medication complexity for older adults in the emergency department of a secondary teaching hospital in Indonesia

Khusnul Fitri Hamidah (), Mahardian Rahmadi (), Farah Meutia (), Prihatma Kriswidyatomo (), Firman Suryadi Rahman (), Zamrotul Izzah (), Bambang Subakti Zulkarnain (), Leopold N. Aminde (), Christopher Paul Alderman (), Yulistiani (), Budi Suprapti ()

Published online: 08-Nov-2022

Received (first version): 01-Sep-2022

ep-2022

Accepted: 19-Sep-2022

Abstract Background: Older adults experience progressive decline in various organs and changes in pharmacokinetics and pharmacodynamics of the drugs in the body which lead to an increased risk of medication-related problems. Potentially inappropriate medications (PIMs) and medication complexity are key factors contributing to adverse drug events in the emergency department (ED). Objective: To estimate the prevalence and investigate the risk factors of PIMs and medication complexity among older adults admitted to the ED. **Methods:** A retrospective observational study was conducted among patients aged > 60 years admitted to the ED of Universitas Airlangga Teaching Hospital in January - June 2020. PIMs and medication complexity were measured using the 2019 American Geriatrics Society Beers Criteria® and Medication Regimen Complexity Index (MRCI), respectively. **Results:** A total of 1005 patients were included and 55.0% (95% confidence interval [CI]: 52 - 58%) of them received at least one PIM. Whereas, the pharmacological therapy prescribed to older adults had a high complexity index (mean MRCI 17.23 + 11.15). Multivariate analysis showed that those with polypharmacy (OR= 6.954; 95% CI: 4.617 - 10.476), diseases of the digestive system (OR= 2.126; 95% CI: 1.166 - 3.876), endocrine, nutritional, and metabolic diseases (OR= 1.924; 95% CI: 1.087 - 3.405), and diseases of the digestive system (OR= 1.858; 95% CI: 1.214 - 2.842) had an increased risk of receiving PIM prescriptions. Meanwhile, disease of the respiratory system (OR = 7.621; 95% CI: 2.833 - 15.150), endocrine, nutritional and metabolic diseases (OR= 2.935 - 14.847), and polypharmacy (OR = 4.373; 95% CI: 3.540 - 5.401) were associated with higher medication complexity. **Conclusion**: In our study, over one in every two older adults admitted to the ED had PIMs, and a high medication complexity was observed. Endocrine, nutritional and metabolic disease was the leading risk factors for receiving PIMs and high medication complexi

Keywords: beers criteria; elderly; medication regimen complexity index; medication-related problem; polypharmacy

Khusnul Fitri HAMIDAH. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia. khusnul.fitri.hamidah-2018@ff.unair.ac.id Mahardian RAHMADI*. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. mahardianr@ff.unair.ac.id Farah MEUTIA. Master of Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga Surabaya, Indonesia. farah.meutia-2020@ff.unair.ac.id Prihatma KRISWIDYATOMO. Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas

and Reanimation, Faculty of Medicine, Universitas Airlangga, Emergency Department, Universitas Airlangga Teaching Hospital, Surabaya, Indonesia. prihatma. kriswidyatomo@staf.unair.ac.id

Firman Suryadi RAHMAN. Doctoral Program of Public Health, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia. firman.suryadi.rahman-2018@fkm. unair.ac.id

Zamrotul IZZAH. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands. zamrotulizzah@ff.unair.ac.id **Bambang Subakti ZULKARNAIN**. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. bambang-s-z@ff.unair.ac.id **Leopold N. AMINDE**. School of Medicine, Griffith University, Gold Coast, QLD, Australia. I.aminde@griffith. edu.au

Christopher Paul ALDERMAN. Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. Chris.Alderman@unisa.edu.au Yulistiani. Department of Pharmacy, Universitas Airlangga Teaching Hospital, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. yulistiani@ff.unair.ac.id Budi SUPRAPTI. Department of Pharmacy, Universitas

Airlangga Teaching Hospital, Department of Pharmacy, Universitas Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. budi-s@ff.unair.ac.id



INTRODUCTION

Potentially inappropriate medication (PIM) is one of the factors causing medication-related problems in older adults.¹⁻³ PIM is a drug with a risk of adverse effects more significant than its benefits when used by older adults, especially if safer alternative therapies are available and provide the same effectiveness.⁴ PIM prescriptions in older adults are a recognized problem for health services, contributing to the increased prevalence of morbidity, hospitalization, and costs.¹

The most frequently used approach to identify the presence of PIM in patients' therapy is the American Geriatrics Society (AGS) Beers Criteria^{*}, an interdisciplinary consensus-based approach that lists drugs categorized as PIM in older adults. The Beers Criteria^{*} is continuously updated and an important measurement tool in identifying PIM to improve the quality and safety of the therapy. Moreover, the Beers Criteria^{*} can be used in various service areas.^{2,5,6}

Older adults experience a progressive decline in various systems and organs. These contribute to increase the prevalence of disease and susceptibility to receive more medications. They receive more than two types of drugs and polypharmacy occurs in 20-50% of these elderly patients.^{5,7} As a consequence, it may put them at high risk of drug-related problems and lead to hospital admission.

Globally, the number of older patients admitted to hospital emergency departments (ED) increase significantly annually, which is in line with the growth in ageing populations and increasing life expectancy.⁸ In 2015, about 13 million patients came to the ED with a history of diabetes in America, 59% of them were older adults.⁹ In Indonesia, almost 25% of people aged > 65 years visit the ED at least once a year, and 8% undergo repeat visits.¹⁰ On the other hand, the ED is a high-risk service area for the occurrence of medication errors in the hospital. Some contributing factors include: (1) patients in emergency conditions; (2) patients of various ages; (3) high use of high alert drugs; (4) treatment is carried out simultaneously on patients; (5) and the lack of ability of health workers to communicate with patients due to the density of services.¹¹

In 2003–2012, the prevalence of PIM in older adults identified by the Beers Criteria[®] increased from 5.6% to 26% in European and Asian countries.¹² Even though older patients get medications in a single dose and for a short time in the ED, some drugs can cause serious side effects. Another study in the United States showed that at least 7% of patients presenting with myocardial infarction required dose adjustment because of actual side effects. In older patients who require more therapy, it is necessary to consider the risk of PIM use and drug interactions¹¹⁻¹³.

Besides PIM, medication regimen complexity also plays a role in drug-related problems and the incidence of readmissions and hospitalizations in elderly patients. Therefore, hospital pharmacists should pay attention to the medication complexity in older patients. The medication regimen complexity index (MRCI) is a validated instrument that can be used to describe the complexity of medications, including drug dosage forms, dosing frequency, and additional directions.^{5,14,15}

To the best of the authors knowledge, there is limited information regarding PIM and medication complexity among the Indonesian population. Previous studies were performed using the 2015 Beers Criteria^{*} and no recent study in Indonesia has been conducted with the updated 2019 version.^{1,16-18} Therefore, to complement this knowledge gap, studies on PIM and medication complexity in older adults visiting the hospital ED in Indonesia are needed to improve patient safety. Moreover, the study results can be utilized to identify older patients at risk of adverse drug events or who require supervision from specialist medical personnels.¹⁴

METHODS

Study design and setting

A retrospective observational study was conducted at the ED of Universitas Airlangga (UNAIR) Teaching Hospital in Indonesia, located in Surabaya, East Java Province, which receives 80-120 emergency patients daily. A clinical pharmacist together with a hospital pharmacist and seven pharmacy technicians provide pharmacy services in the ED, such as reviewing prescribed medicines, drug reconciliation, working collaboratively with physicians and nurses to control patients with intoxication.¹⁹

Data were extracted from patient medical records admitted to the ED during January to June 2020 (Figure 1). The study protocol was approved by the Ethics committee of UNAIR Teaching Hospital (Approval certificate no.177/KEP/2020) prior to the commencement of the study.




Figure 1. Study enrolment flowchart

Data collection

Data were recorded on the data collection sheet and kept confidential during collection. Data collection included demographic (gender, year of birth or age, occupation), clinical characteristics (triage level, underlying diseases or diagnosis, comorbidities), laboratory and supporting examinations (serum



https://doi.org/10.18549/PharmPract.2022.4.2735

electrolytes, creatinine, blood glucose, full blood count), and prescribed medications (active substance, strength, dosage form, route of administration, dosing frequency, and additional instructions, if applicable).

Diseases classification and comorbidity

A classification of diseases was carried out using the International Classification of Diseases and Related Health Problems, tenth revision (ICD-10).²⁰ In addition, the comorbidity index was calculated using the validated Charlson Comorbidity Index (CCI).¹⁶ The prevalence of each disease group and comorbid index were further calculated.

Potentially inappropriate medications assessment

The primary outcome of this study was the prevalence and risk factors for PIMs in older adult patients in the ED. PIMs were analyzed based on the 2019 AGS Beers Criteria[®]. We summarised the PIM assessment in our study population in a tabular format according the type and number of PIMs in each category.

Medication regimen complexity assessment

As the secondary outcome, the medication regimen complexity was measured using the validated MRCI,¹⁴ which includes 65 assessment items categorized. The complexity index was assessed for each therapy received by older adult patients based on predetermined parameters and values, namely: (1) dosage forms; (2) dosing frequency; and (3) additional directions.¹³ Then, the values obtained in each subgroup were summed, tabled and classified to get the mean of MRCI as a cut-off point for high complexity category. A higher MRCI score indicates higher complexity.

Statistical analysis

Descriptive analysis was done by summarising the categorical variables as counts with percentages and continuous variables as means with standard deviation. Continuous variables checked using the Kolmogorov-Smirnov test. The prevalence of PIM was estimated by dividing the number of older patients by the total study population. We conducted univariate binary logistic regression analyses to investigate factors associated with PIM use and MRCI. The following factors were tested: diseases groups by ICD-10 classification, comorbidities, and the number of prescribed medications. To determine factors that were independently associated with PIM use and high medication complexity, all factors that were statistically significant in the univariate analyses were used to build a multivariate logistic regression model. All statistical analyses were carried out in the Statistical Package for the Social Sciences (SPSS) version 25 with a significance level of α = 0.05.

RESULTS

General characteristics

In this study, a total of 1005 emergency visits of patients aged \geq 60 years with a yellow or red triage and received at least one




Table 1. Demographic and clinical characteristics of emergency	visit cases
Variable	n (%)
No. of visits 1005	
Gender Male Female	495 (49.3) 510 (50.7)
Age (years) 60 - 64 65 - 69 70 - 74 ≥ 75	314 (31.2) 283 (28.2) 189 (18.8) 219 (21.8)
ED triage Yellow Red	746 (74.2) 259 (25.8)
Charlson Comorbidity Index No comorbidity (0) Mild $(1-2)$ Moderate $(3-4)$ Severe (\geq 5)	411 (40.9) 559 (55.6) 32 (3.2) 3 (0.3)
Disease groups (ICD-10) Diseases of the respiratory system Diseases of the digestive system Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	194 (19.3) 177 (17.6) 155 (15.4)
Diseases of the circulatory system Diseases of the nervous system Endocrine, nutritional and metabolic diseases Diseases of the genitourinary system	107 (10.6) 94 (9.4) 94 (9.4) 61 (6.1)
Injury, poisoning and certain other consequences of external causes Certain infectious and parasitic diseases Diseases of musculoskeletal system and connective tissue Diseases of the skin and subcutaneous tissue Neoplasms	37 (3.7) 32 (3.2) 23 (2.3) 13 (1.3) 10 (1.0)
Diseases of the blood and blood-forming organs Disorders of gallbladder, biliary tract and pancreas	5 (0.5) 3 (0.3)
Number of prescribed medications < 5 ≥ 5 (polypharmacy)	712 (70.8) 293 (29.2)
Condition after ED visit Hospitalization Discharge	652 (64.9) 353 (35.1)
ED emergency department, ICD international classification of di	seases

Potentially inappropriate medications

Based on visit cases, at least one PIM was prescribed in more than half patients (55.0%, 95% confidence interval [CI]: 52 – 58%) and 62.3% of those were potentially inappropriate use in most older adults PIM criteria. The prevalence and classification of PIM are shown in Table 2. The list of top ten drugs categorized as PIM received by elderly patients in the ED is shown in Table 3. Metoclopramide was the most prescribed PIM (16.6%), followed by omeprazole (10.4%).




Table 2.Frequency of visit cases with potentially inappropriamedications according to the 2019 AGS Beers Criteria®	te
	n (%)
Number of PIM	
Visit without PIM	452 (45.0)
Visit with PIM	553 (55.0)
1 2 3 4 5 6	359 (35.7) 141 (14.0) 40 (4.0) 10 (1.0) 2 (0.2) 1 (0.1)
PIM Criteria	
PIM use in older adults	512 (62.3)
PIM use in older adults due to drug-disease or drug-syndrome interactions that may exacerbate the disease or syndrome	48 (5.8)
PIM to be used with caution	192 (23.4)
PIM that should be avoided due to drug interactions	18 (2.2)
PIM that should be avoided or require dose adjustment due to decreased renal function	52 (6.3)
Therapeutic category	
Gastrointestinal medications	352 (43.1)
Diuretics	123 (15.1)
Nonsteroidal anti-inflammatory drugs	103 (12.6)
Endocrine medications	92 (11.3)
Antiplatelet aggregation	74 (9.1)
Benzodiazepines	20 (2.40
Antispasmodic	17 (2.1)
Cardiovascular medications	15 (1.8)
Corticosteroid	7 (0.9)
Anticoagulant	3 (0.4)
Antihistamine	2 (0.2)
Narcotic analgesics	1 (0.1)
Antidepressants	1 (0.1)
Central nervous system and analgesics drugs	1 (0.1)
AGS American Geriatric Society, PIM potentially inappropriate n	nedication

Factors associated with PIM use

From the univariate analysis, we found that having diseases of the respiratory system, digestive system, presence of symptoms, signs and abnormal clinical and laboratory findings, circulatory system, endocrine, nutritional and metabolic diseases, genitourinary system, presence of neoplasms and patients with polypharmacy had p-values < 0.25 and were considered candidate variables for inclusion in the multivariable model.

Our multivariate analysis showed that those with circulatory system diseases (OR = 2.126; 95% CI: 1.166–3.876), endocrine, nutritional and metabolic diseases (OR = 1.924; 95% CI: 1.087–3.405), and digestive system diseases (OR = 1.858; 95% CI: 1.214 – 2.842) had increased likelihood of being prescribed PIMs compared to their counterparts, while those with diseases



of the respiratory system (OR = 0.183; 95% CI: 0.112-0.302), symptoms, signs, and abnormal clinical and laboratory findings (OR = 0.668; 95% CI: 0.430 - 1.036) had lower odds of being prescribed PIMS compared to their counterparts who did not have these conditions. Table 4 depicts our regression results for factors associated with the use of PIMs in elderly patients in the ED.

Medication regimen complexity

The mean of MRCI scores was 17.23 ± 11.15 with cut-off upper quartile, thus the scores were categorized into two groups: high complexity with MRCI score ≥ 24 and low with MRCI score < 24. Our multivariate analysis showed that those with respiratory system disease (OR = 7.621; 95% CI: 2.833–5.150), and endocrine, nutritional and metabolic diseases (OR = 6.601; 95% CI: 2.935–14.847) were highly correlated with MRCI scores, while those with musculoskeletal system and connective tissue disease (OR = 1.974; 95% CI: 0.175 – 22.209), nervous system disease (OR = 1.746; 95% CI: 0.530 – 5.746), and symptoms,



Hamidah KF, Rahmadi M, Meutia F, Kriswidyatomo P, Rahman FS, Izzah Z, Zulkarnain BS, Aminde LN, Alderman CP, Yulistiani, Suprapti B. Prevalence and factors associated with potentially inappropriate medication and medication complexity for older adults in the emergei .2735

ency department of a secondary teaching hospital in Indonesia. Pharmad	cy Practice 2022 Oct-Dec;20(4):2735.
	https://doi.org/10.18549/PharmPract.2022.4.2

Indonesia, 2020	DINA			-**	NALILIAN COLOR		
Variable	PIM prescri	1	Univariate analysis	\$**	Multivariate analy		
	Yes n (%)	No n (%)	Odds ratio (95% CI)	p-value	Odds ratio (95% CI)	p-value	
Disease group*		1		1	-		
Diseases of the respiratory system							
Yes No	61 (11.0) 492 (89.0)	133 (29.4) 319 (70.6)	0.297 (0.213 – 0.415)	0.000	0.183 (0.112 – 0.302)	0.000	
Diseases of the digestive system			(0.220 0.120)		(0.112 0.002)		
Yes	115 (20.8)	62 (13.7)	1.652	0.004	1.858	0.004	
No Symptoms, signs and abnormal clinical and laboratory findings,	438 (79.2)	390 (86.3)	(1.178 – 2.315)		(1.214 – 2.842)		
not elsewhere classified							
Yes No	63 (11.4) 490 (88.6)	92 (20.4) 360 (79.6)	0.503 (0.355 – 0.713)	0.000	0.668 (0.430 – 1.036)	0.071	
Diseases of the circulatory system							
Yes No	87 (15.7) 466 (84.3)	20 (4.4) 432 (95.6)	4.033 (2.438 – 6.671)	0.000	2.126 (1.166 – 3.876)	0.014	
Diseases of the nervous system	+00 (04.3)	+52 (55.0)	(2.450 - 0.071)		(1.100 - 3.870)		
Yes	49 (8.9)	45 (10.0)	0.879	0.553	-	-	
No	504 (91.1)	407 (90.0)	(0.575 – 1.345)				
Endocrine, nutritional and metabolic diseases Yes	70 (12.7)	24 (5.3)	2.585	0.000	1.924	0.025	
No	483 (87.3)	428 (94.7)	(1.597 – 4.183)		(1.087 – 3.405)		
Diseases of the genitourinary system Yes	42 (7.6)	19 (4.2)	1.873	0.027	1.669	0.117	
No	511 (92.4)	433 (95.8)	(1.073 – 3.269)	0.027	(0.879 – 3.166)	0.117	
Injury, poisoning and certain other consequences of external							
causes Yes	17 (3.1)	20 (4.4)	0.685	0.261		_	
No	536 (96.9)	432 (95.6)	(0.354 – 1.324)		-	-	
Certain infectious and parasitic diseases Yes	16 (2.9)	16 (3.5)	0.812	0.562	_	_	
No	537 (97.1)	436 (96.5)	(0.401 – 1.642)				
Diseases of musculoskeletal system and connective tissue	14 (2 5)	0 (2 0)	1 270	0 700			
Yes No	14 (2.5) 539 (97.5)	9 (2.0) 443 (98.0)	1.278 (0.548 – 2.982)	0.700	-	-	
Diseases of the skin and subcutaneous tissue							
Yes No	6 (1.1) 547 (98.9)	7 (1.5) 445 (98.5)	0.697 (0.233 – 2.090)	0.520	-	-	
Neoplasms		- (/					
Yes No	8 (1.4) 545 (98.6)	2 (0.4) 450 (99.6)	3.303 (0.698 – 15.631)	0.132	3.327 (0.656 – 16.878)	0.147	
Diseases of the blood and blood-forming organs	545 (58.0)	450 (55.0)	(0.058 15.051)		(0.050 10.878)		
Yes	3 (0.5)	2 (0.4)	1.227	0.823	-	-	
No	550 (99.5)	450 (99.6)	(0.204 – 7.377)				
Disorders of gallbladder, biliary tract and pancreas Yes	2 (0.4)	1 (0.2)	1.637	0.668	-	-	
No	551 (99.6)	451 (99.8)	(0.148 – 18.112)				
Charlson Comorbidity Index		1	1	1		1	
No comorbidity (0)	209 (37.8)	202 (44.7)	-	-	-	-	
Mild (1 – 2)	320 (57.9)	239 (52.9)	0.517 (0.047 – 5.750)	0.592	-	-	
Moderate (3 – 4)	22 (4.0)	10 (2.2)	0.669 (0.060 – 7.426)	0.744	-	-	
Severe (≥ 5)	2 (0.4)	1 (0.2)	1.100 (0.089 – 13.592)	0.941	-	-	



ttps·/	/doi org	/10 18549	/PharmPract	2022.4.2735
11103./	/ uui.uig/	10.10040	/	2022.4.2/33

	PIM prescription		Univariate analysis**		Multivariate analysis***	
Variable	Yes n (%)	No n (%)	Odds ratio (95% CI)	p-value	Odds ratio (95% CI)	p-value
Number of prescribed medications						
<5	325 (58.8)	387 (85.6)	-	-	-	-
≥ 5 (polypharmacy)	228 (41.2)	65 (14.4)	4.177 (3.056 – 5.709)	0.000	6.954 (4.617 – 10.476)	0.000
*Disease groups according to the ICD-10						
**p-value < 0,05; 95% CI (univariate analysis)						

signs and abnormal clinical findings (OR = 1.502; 95% CI: 0.588 – 3.836) were not associated with MRCI score. Table 5 depicts our regression results for factors associated with high complexity use among elderly patients in the ED.

DISCUSSION

PIM is one of the most common drug-related problems encountered in older adults and negatively impacts patients' health and quality of life and also susceptible to medication complexity, contributing to adverse drug effects and elevated risk of unplanned hospitalization.^{15,21-23} This study revealed that over half of the elderly patients in the ED of UNAIR Teaching Hospital received PIMs. Over a third of them received at least one PIM and about two-thirds of PIM use was within the 'PIM use in older adults' category of the 2019 AGS Beers Criteria[®]. Our results are consistent with research conducted by Sharma et al. on the prevalence of PIM in 323 elderly patients at Guru Gobind Singh Medical College and Hospital, Punjab using the 2019 Beers Criteria®, which demonstrated that 61.9% of prescriptions were PIMs.²⁴ Previous studies have estimated the prevalence of PIMs using the 2015 Beers Criteria® albeit in varied health care settings and found similar results to ours, such as in Jordan (49.2% to 62.5% among older patients),^{25,26} Saudi Arabia (61% geriatrics),²⁷ and comparatively lower prevalence was found Japan (47.9% elderly patients),²⁸ and Pennsylvania (35.8% elderly patients).²⁹ Recent studies using the 2019 Beers Criteria® conducted in the United Arab Emirates found that 34.7% and in China, about 74.1% of elderly patients had at least one PIM, which is more than double the finding in our study.30,31

This study showed that the most common group of diseases among older adults in the ED was digestive system disorders. In addition, the most widely used PIMs came from the gastrointestinal therapeutic class (43.1%), diuretics (15.1%), and nonsteroidal anti-inflammatory drugs (12.6%). This finding is in line with a study conducted in Qatar, which showed that the most commonly used PIMs were drugs listed in gastrointestinal (84.2%) and analgesics (49.9%).³² Although PIMs prescriptions generally occur in chronic therapy, our study showed that PIMs could also happen in acute therapy. We found that gastrointestinal drugs (i.e., metoclopramide and omeprazole) were the most common PIM. Metoclopramide was reported to reach 25% extrapyramidal effects.³³ Another study conducted in Brazil reported that 41% of elderly patients received metoclopramide.³⁴ Jeon et al. also showed that in 79,552 elderly patients in South Korea, metoclopramide was one of the most frequently used PIMs (22%).³⁵ On the other hand, omeprazole poses a risk of Clostridium difficile infection especially in long-term use.^{4,36} A study in Brazil showed that about a third of the elderly patients received for omeprazole. They further reported that 63% of the omeprazole prescriptions were not indicated.³⁴ Omeprazole, a proton pump inhibitor (PPI) is used for treating gastric acid disorders.³⁷

Some patient-related factors make older adults more susceptible to receiving PIMs in the ED. Our multivariate analyses showed that patients with circulatory system disorders had the highest probability, that is, compared to their counterparts, were two times as likely to get PIMs. Although diseases of the circulatory system were not the most common disease group, the therapeutic profile of cardiovascular patients put them at high risk of receiving PIM in the ED. In Pakistan, a prior study showed that nearly three-quarters of elderly patients with cardiovascular diseases had at least one PIM.³⁸ Furthermore, a European study using the START/STOPP screening criteria found similar results, where 61.5% of elderly patients with cardiovascular disorders received PIM.³⁹ Sheikh-Taha and Dimassi also reported that 87.4% of elderly patients visiting the USA cardiology unit received at least one PIM.⁴⁰ These findings suggest a need for close monitoring and caution in treating patients with cardiovascular disorders.

This research also pointed out that number of medications received by older adults had a significant effect on the prevalence of PIMs in the ED (p < 0.005). Elderly patients who received polypharmacy had a risk of experiencing PIM by 6.954 times than older adults who received fewer medications. Alhawassi et al. signified that elderly patients who received polypharmacy were 7.79 times more likely to receive PIM.⁴¹ Other studies conducted in Turkey and Sweden also stated that there was a significant effect of polypharmacy on the number



of PIM (p < 0.001).^{42,43}

Aside from potentially inappropriate prescribing, medication complexity also plays a role in drug-related problems. Research conducted by Wimmer et al. supported this finding that comorbidities lead the patients to be treated with more complex medication.¹⁵ In terms of disease groups, elderly patients have a reasonably varied MRCI score. For example, patients' endocrine diseases are more likely to receive additional directions for diabetes management. These likely contribute to increasing the prevalence of complex therapy, as observed in our study. This finding is supported by a prior study which stated that 60% of patients with diabetes mellitus received medications with high complexity (MRCI >16.5).⁴⁴

Regarding the number of medications, 77.1% of older adults received polypharmacy with high medication complexity (MRCI \geq 24). This finding follows the results of the study of Ferreira et al., where 74.2% of patients who received polypharmacy had high MRCI values (MRCI > 13.0). Another study also showed that 37.5% of elderly patients with polypharmacy had at least

an MRCl > 16.5.44 Moreover, dosage form, dosing frequency, and specific drug instructions also contribute to the MRCI value. In this study, the dosage form contributed to the highest average complexity value compared to dosing frequency and additional directions for drug use. Pantuzza et al. reported that among the three components of the medication regimen complexity assessment in two primary healthcare units, the dosing frequency contributed the highest average complexity value with an average MRCI lower than the results of our study. The findings from our study differ from previous studies in part because of differences in the study setting. Most of the medicines prescribed in the ED were for parenteral use, which requires sufficient knowledge (route and time of administration) to avoid medication administration errors. As a result, we found that the dosage form had the highest MRCI values.45

Furthermore, our study showed disease of respiratory system andendocrine, nutritional and metabolic diseases had a strong association with MRCI value in the disease group, while the rest were very weak associated (Table 5).

		MRCI		Univariate analysis		Multivariate analysis	
Variable	MRCI	Low (<24)	High (≥24)	Odds ratio		Odds ratio	p-value
	mean ± SD	n (%)	n (%)	(95% CI)	p-value	(95% CI)	
MRCI assessment					•		
Dosage forms	10.95 ± 6.401						
Dosing frequency	5.51 ± 4.980						
Additional instructions	0.78 ± 1.440						
Disease group							
Diseases of the respiratory system							
Yes		99 (13.3)	95 (36.8)	3.815	0.000	7.621	0.000
No		648 (86.7)	163 (63.2)	(2.743 – 5.305)	0.000	(3.833 – 15.150)	
Diseases of the digestive system				•			
Yes		154 (20.6)	23 (8.9)	0.377	0.000	2.911	0.009
No		593 (79.4)	235 (91.1)	(0.237 – 0.599)	0.000	(1.312 – 6.459)	
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified							
Yes		142 (19.0)	13 (5.0)	0.226	0.000	1.502	0.205
No		605 (81.0)	245 (95.0)	(0.126 – 0.407)	0.000	(0.588 – 3.836)	0.395
Diseases of the circulatory system							
Yes		78 (10.4)	29 (11.2)	1.086	0.720	-	
No		669 (89.6)	229 (88.8)	(0.691 –1.707)	0.720	-	-
Diseases of the nervous system							
Yes		85 (11.4)	9 (3.5)	0.282	0.000	1.746	0.250
No		662 (88.6)	249 (96.5)	(0.139 – 0.568)	0.000	0.530 – 5.746	0.359
Endocrine, nutritional and metabolic diseases							
Yes		52 (7.0)	42 (16.3)	2.599	0.000	6.601	0.000
No		695 (93.0)	216 (83.7)	(1.683 – 4.012)	0.000	(2.935 – 14.847)	0.000



https://doi.org/10.18549	/PharmPract.2022.4.2735
--------------------------	-------------------------

Diseases of the genitourinary system						
Yes	42 (5.6)	19 (7.4)	1.334	0.214	-	
No	705 (94.4)	239 (92.6)	(0.761 – 2.339)	0.314		-
Injury, poisoning and certain other consequences of external causes						
Yes	29 (3.9)	8 (3.1)	0.792	0.566	-	-
No	718 (96.1)	250 (96.9)	(0.357 – 1.756)	0.566	-	
Certain infectious and parasitic diseases						
Yes	21 (2.8)	11 (4.3)	1.540	0.255	-	
No	726 (97.2)	247 (95.7)	(0.732 – 3.239)	0.255	-] -
Diseases of musculoskeletal system and connective tissue						
Yes	22 (2.9)	1 (0.4)	0.128	0.045	1.974	0.582
No	725 (97.1)	257 (99.6)	(0.017 – 0.956)	0.045	0.175 – 22.209	
Diseases of the skin and subcutaneous tissue						
Yes	10 (1.3)	3 (1.2)	0.867		-	-
No	737 (98.7)	255 (98.8)	(0.237 – 3.175)	0.829	-	
Neoplasms						
Yes	6 (99.2)	4 (98.4)	1.945	0.306	-	-
No	741 (0.8)	254 (1.6)	(0.544 – 6.947)		-	
Diseases of the blood and blood-forming organs						
Yes	4 (0.5)	1 (0.4)	0.723	0.770	-	
No	743 (99.5)	257 (99.6)	(0.080 - 6.496)	0.772	-	
Disorders of gallbladder, biliary tract and pancreas					•	
Yes	3 (0.4)	0 (0.0)	0.000		-	
No	774 (99.6)	258 (100.0)	(0.000 –)	0.999	-	
Charlson Comorbidity Index						
No comorbidity (0)	325 (79.1)	86 (20.9)	-	-	-	-
Mild (1 – 2)	402 (71.9)	157 (28.1)	0.132 (0.012 - 1.476)	0.100	-	-
Moderate (3 – 4)	19 (59.4)	13 (40.6)	0.195 (0.018 – 2.169)	0.184	-	-
Severe (≥ 5)	1 (33.3)	2 (66.7)	0.342 (0.028 - 4.176)	0.401	-	-
Number of prescribed medications	· · · · · · · · · · · · · · · · · · ·					
<5	680 (95.5)	32 (4.5)	4.011	-	4.373	-
≥5 (polypharmacy)	67 (22.9)	226 (77.1)	(3.345 – 4.809)	0.000	(3.540 - 5.401)	0.000
MRCI medication regimen complexity index	·					

This study also found that polypharmacy had a strong correlation with the MRCI value. This is in line with previous studies, which denoted that the number of medications and changes in the dosing frequency associated with the MRCI value (p < 0.001).⁴³ Additionally, Advinha et al. described that MRCI value would increase by increasing therapy⁴⁵ and greater MRCI scores are predictive of readmission to hospital.⁴⁷

This study has several limitations. First, we did not assess all drugs listed on the 2019 AGS Beers Criteria[®] available due to hospital formulary at the research site and this single-center study limits the generalizability of the findings beyond the

catchment area served by the study center. Nevertheless, our relatively large number of visits increases the power of the study and limits the possibility of type 1 error.

Moreover, to our knowledge, this study is the first to be conducted in Indonesia to assess the prevalence and risk factors for PIM (using the 2019 AGS Beers Criteria[®]) and medication complexity (using MRCI) among older adults. In addition, the study was conducted in the ED, which has a specificity of the intervention in services. Therefore, our findings will serve as a benchmark for future studies exploring other determinants of PIM use and the medication regimen complexity in Indonesia.

https://doi.org/10.18549/PharmPract.2022.4.2735

There are no studies that state the cut-off value of MRCI, which can be a reference for categorizing high treatment complexity. Based on the data we collected, it is suggested that future research is needed with varied backgrounds (country, service setting, disease, and number of drugs) and need for some validation and reliability study on the MRCI to be able to determine a universally acceptable cut-off value to define medication complexity are high, moderate or low. Hopefully, after knowing the complexity threshold, PIM and high medication complexity can be controlled to improve patient safety and develop health intervention strategies.

Our study found that more than half of older adults admitted

CONCLUSION

to the ED had PIMs, and a high medication complexity was observed. Patients with disease of Endocrine, nutritional and metabolic disease was risk factors for both PIMs and medication regimen complexity. A strict monitoring and vigilance are needed on PIMs and medication regimen complexity in the elderly with disease groups mentioned in this research to prevent the potential adverse impacts on vulnerable patients and improve the health system.

ACKNOWLEDGEMENT

The authors would like to express our gratitude to Arina Dery Puspitasari and Ahmad Dzulfikri Nurhan for their support on this project.

References

- 1. Zhang X, Zhou S, Pan K, et al. Potentially Inappropriate Medications in Hospitalized Older Patients: A Cross-sectional Study Using The Beers 2015 Criteria versus the 2012 criteria. Clin Interv Aging. 2017;12:1697-1703. https://doi.org/10.2147/CIA. S146009
- 2. Curtin D, Gallagher P F, O'Mahony D. Explicit criteria as clinical tools to minimize inappropriate medication use and its consequences. Ther Adv Drug Saf. 2019;10:1-10. https://doi.org/10.1177/2042098619829431
- 3. Thorell K, Midlöv P, Fastbom J, et al. Importance of potentially inappropriate medications, number of chronic conditions and medications for the Risk of hospitalisation in elderly in Sweden: a case-control study. BMJ Open. 2019;9(9):1-9. https://doi. org/10.1136/bmjopen-2019-029477
- 4. 2019 American Geriatrics Society Beers Criteria[®] Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria[®] for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694. https://doi. org/10.1111/jgs.15767
- 5. Chang WT, Kowalski SR, Sorich W, et al. Medication regimen complexity and prevalence of potentially inappropriate medicines in older patients after Hospitalisation. Int J Clin Pharm. 2017;39(4):867-873. https://doi.org/10.1007/s11096-017-0490-y
- 6. Khamis S, Abdi AM, Uzan A, Basgut B. Applying Beers Criteria for elderly patients to assess rational drug use at a university hospital in Northern Cyprus. J Pharm Bioallied Sci. 2019;11(2):133. https://doi.org/10.4103/jpbs.JPBS_208_18
- 7. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. https://doi. org/10.1080/03602530902722679
- 8. Legramante JM, Morciano L, Lucaroni F, et al. Frequent use of emergency departments by the elderly population when continuing care is not well established. PLoS One. 2016;11(12):e0165939. https://doi.org/10.1371/journal.pone.0165939
- 9. Hall MJ, Rui P, Schwartzman A. Emergency Department Visits by Patients Aged 45 and over with Diabetes. 2018.
- Rizka A, Harimurti K, Pitoyo CW, et al. Performa rapid emergency medicine score (REMS) dalam memprediksi mortalitas 30 hari pasien usia lanjut di instalasi gawat darurat. J. Penyakit Dalam Indones. 2017;4(2):62-67. http://dx.doi.org/10.7454/jpdi. v4i2.116
- 11. Farmer M. Strategies aimed at improving medication safety, transitions of care, health information technology, and other factors in the ED can significantly decrease the risks of adverse events. Emerg. Med. 2016;(48):397-404.
- 12. Chang CB, Lai HY, Hwang SJ, et al. Prescription of potentially inappropriate medication to older patients presenting to the emergency department: a nationally representative population study. Sci Rep. 2018;8(1):1-8. https://doi.org/10.1038/s41598-018-30184-4
- 13. Reis CM, dos Santos AG, de Jesus Souza P, et al. Factors associated with the use of potentially inappropriate medications by older adults with cancer. J Geriatr Oncol. 2017;8(4):303-307. https://doi.org/10.1016/j.jgo.2017.05.003
- 14. George J, Phun YT, Bailey MJ, et al. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38:1369-1376. https://doi.org/10.1345/aph.1D479
- 15. Wimmer BC, Johnell K, Fastbom J, et al. Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. Eur J Clin Pharmacol. 2015;71(9);1099-1108. <u>https://doi.org/10.1007/s00228-015-1883-2</u>
- 16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. <u>https://doi.org/10.1016/0021-9681(87)90171-8</u>
- 17. Blanco-Reina E, Valdellós J, Aguilar-Cano L, et al. 2015 Beers Criteria and STOPP v2 for detecting potentially inappropriate medication in community-dwelling older people: prevalence, profile, and risk factors. Eur J Clin Pharmacol. 2019;75(10):1459-



https://doi.org/10.18549/PharmPract.2022.4.2735

1466. https://doi.org/10.1007/s00228-019-02722-0

- Federman AD, O'conor R, Wolf MS, et al. Associations of Medication Regimen Complexity with COPD Medication Adherence and Control. Int J Chron Obstruct Pulmon Dis. 2021;16:2385. <u>https://doi.org/10.2147/COPD.S310630</u>
- 19. Farmer BM, Hayes BD, Rao R, et al. The role of clinical pharmacists in the emergency department. J. Med. Toxicol. 2018;14(1):114-116. <u>https://doi.org/10.1007/s13181-017-0634-4</u>
- 20. WHO. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2019.
- 21. Simões PA, Santiago LM, Maurício K, et al. Prevalence of potentially inappropriate medication in the older adult population within primary care in Portugal: a nationwide cross-sectional study. Patient Prefer Adherence. 2019;13:1569-1576. <u>https://doi.org/10.2147/PPA.S219346</u>
- 22. Sharma R, Bansal P, Garg R, et al. Prevalence of potentially inappropriate medication and its correlates in elderly hospitalized patients: A cross-sectional study based on Beers criteria. J Fam Community Med. 2020:27(3):200-207. <u>https://doi.org/10.4103/jfcm.JFCM_175_20</u>
- 23. Price SD, Holman CDAJ, Sanfilippo FM, et al. Association between potentially inappropriate medications from the Beers criteria and the risk of unplanned hospitalization in elderly patients. Annals of Pharmacotherapy. 2014;48(1):6-16. <u>https://doi.org/10.1177/1060028013504904</u>
- 24. Xing XX, Zhu C, Liang HY, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. Annals of Pharmacotherapy. 2019;53(10):1005-1019. <u>https://doi.org/10.1177/1060028019853069</u>
- 25. Al-Azayzih A, Alamoori R, Altawalbeh SM. Potentially inappropriate medications prescribing according to beers criteria among elderly outpatients in jordan: A cross sectional study. Pharm Pract (Granada). 2019;17(2):1-7. <u>https://dx.doi.org/10.18549/pharmpract.2019.2.1439</u>
- Khader H, Hasoun LZ, Alsayed A, et al. Potentially inappropriate medications use and its associated factors among geriatric patients: a cross-sectional study based on 2019 Beers Criteria. Pharmacia. 2021;68(4):789-795. <u>https://doi.org/10.3897/pharmacia.68.e73597</u>
- 27. Najjar MF, Sulaiman SAS, Al Jeraisy M, et al. The impact of a combined intervention program: An educational and clinical pharmacist's intervention to improve prescribing pattern in hospitalized geriatric patients at King Abdulaziz Medical City in Riyadh, Saudi Arabia. Ther Clin Risk Manag. 2018;14:557-564. <u>https://doi.org/10.2147/TCRM.S157469</u>
- 28. Komagamine J. Prevalence of potentially inappropriate medications at admission and discharge among hospitalised elderly patients with acute medical illness at a single centre in Japan: A retrospective cross-sectional study. BMJ Open. 2018;8(7):1-8.
- 29. Abraham DS, Nguyen TP, Hennessy S, et al. Frequency of and risk factors for potentially inappropriate medication use in parkinson's disease. Age Ageing. 2020;49(5):786-792. <u>https://doi.org/10.1093/ageing/afaa033</u>
- 30. Abdelwahed AA, El-Dahiyat F, Aljawamis D, et al. Potentially inappropriate medications in older adults according to Beers criteria 2019: Prevalence and risk factors. Int J Clin. Pract. 2021;75(11):1-8. <u>https://doi.org/10.1111/ijcp.14715</u>
- 31. Tian F, Li H, Chen Z, et al. Potentially inappropriate medications in Chinese older outpatients in tertiary hospitals according to Beers criteria: A cross-sectional study. Int J Clin Pract. 2021;75(8):1-9. <u>https://doi.org/10.1111/ijcp.14348</u>
- 32. Al-Dahshan A, Kehyayan V. Prevalence and predictors of potentially inappropriate medication prescription among older adults: a cross-sectional study in the State of Qatar. Drugs - Real World Outcomes. 2021;8(1):95-103. <u>https://doi.org/10.1007/ s40801-020-00220-9</u>
- 33. Jo YY, Kim YB, Yang MR, Chang YC. Extrapyramidal side effects after metoclopramide administration in a post-anesthesia care unit A case report -. Korean J Anesthesiol. 2012;63(3):274-276. <u>https://doi.org/10.4097/kjae.2012.63.3.274</u>
- 34. Gorzoni ML, Rosa RF. Beers AGS 2019 criteria in very old hospitalized patients. Rev Assoc Med Bras. 2020;66(7):918-923. https://doi.org/10.1590/1806-9282.66.7.918
- 35. Jeon HL, Park J, Han E, et al. Potentially inappropriate medication and hospitalization/emergency department visits among the elderly in Korea. Int J Qual Heal Care. 2018;30(1):50-56. <u>https://doi.org/10.1093/intqhc/mzx171</u>
- 36. DePestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26(5):464-475. <u>https://doi.org/10.1177/0897190013499521</u>
- 37. Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273-297. <u>https://doi.org/10.1177/2042098617715381</u>
- Saqlain M, Ali H, Kamran S, Munir MU, Jahan S, Mazhar F. Potentially inappropriate medications use and its association with health-related quality of life among elderly cardiac patients. Qual Life Res. 2020;29(10):2715-2724. <u>https://doi.org/10.1007/ s11136-020-02530-5</u>
- 39. Abegaz TM, Birru EM, Mekonnen GB. Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria. PLoS One. 2018;13(5):1-14. <u>https://doi.org/10.1371/journal.pone.0195949</u>
- 40. Sheikh-Taha M, Dimassi H. Potentially inappropriate home medications among older patients with cardiovascular disease admitted to a cardiology service in USA. BMC Cardiovasc Disord. 2017;17(1):1-6. <u>https://doi.org/10.1186/s12872-017-0623-1</u>
- 41. T. Alhawassi, W. Alatawi, and M. Alwhaibi. Prevalence of potentially inappropriate medications use among older adults and



risk factors using the 2015 American Geriatrics Society Beers Criteria. BMC Geriatr. 2019;19(1):1-8.. <u>https://doi.org/10.1186/</u> s12877-019-1168-1

- 42. Temrel T, Şahin S. Polypharmacy and potentially inappropriate medication use in geriatric patients presenting to the emergency department. Turk Geriatr Derg. 2019;22(1):25-31.
- 43. Thorell K, Midlöv P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. BMC Geriatr. 2020;20(1):73. <u>https://doi.org/10.1186/s12877-020-1476-5</u>
- Pantuzza LLN, das Graças Braga Ceccato M, Reis EA, Silveira MR, Almeida-Brasil CC, Almeida TA, Pinto IVL, Reis AMM. Factors associated with high medication regimen complexity in primary care older adults in Brazil. Eur Geriatr Med. 2020;11(2):279-287. <u>https://doi.org/10.1007/s41999-019-00275-0</u>
- 45. Parveen, N, Afzal M, Hussain M, Gilani SA. Knowledge regarding Safe Administration of Parenteral Medication among Nurses. Eur Acad Res. 2019;7(1).
- 46. Advinha AM, De Oliveira-Martins S, Mateus V, et al. Medication regimen complexity in institutionalized elderly people in an aging society. Int J Clin Pharm. 2014;36(4);750-756. <u>https://doi.org/10.1007/s11096-014-9963-4</u>
- 47. Wilson MN, Greer CL, Weeks DL. Medication regimen complexity and hospital readmission for an adverse drug event. Annals of Pharmacotherapy. 2013;48(1):26-32. https://doi.org/10.1177/1060028013510898



IR – PERPUSTAKAAN UNIVERSITAS AIRLANGGA

Lampiran 1



KOMITE ETIK PENELITIAN RUMAH SAKIT UNIVERSITAS AIRLANGGA

KETERANGAN LOLOS KAJI ETIK No :177/KEP/2020

Komite Etik Penelitian Rumah Sakit Universitas Airlangga dalam upaya melindungi hak asasi dan kesejahteraan subyek penelitian, telah mengkaji dengan teliti protokol penelitian yang berjudul:

Analisis Potentially Inappropriate Medications (PIMs) dan Kompleksitas Regimen Terapi pada Pasien Lanjut Usia

Peneliti : Khusnul Fitri Hamidah

Institusi Penelitian : Rumah Sakit Universitas Airlangga

DINYATAKAN LAIK ETIK.

Surabaya, 16 September 2020
Prof. Dr. Muhammad Amin,dr.,Sp.P (K) NIDK 8804680018

Keterangan Lolos Kaji Etik berlaku 1 (satu) tahun sejak tanggal penetapan

Jika dalam kurun waktu 1 (satu) tahun penelitian masih belum selesai, maka penelitian akan dihentikan dan peneliti diwajibkan melakukan perpanjangan Keterangan Lolos Kaji Etik

STAND OUT WITH - 35m+ academic resources - Unlimited downloads QUALITY RESEARCH - Latest articles from leading publis								
^							also developed by scimago:	SCIMAGO INSTITUTIONS RANKINGS
SJR	Scimago Journal & Country Rank							
		Home	Journal Rankings	Country Rankings	Viz Tools	Help	About Us	
							(i) ×	
		Teste de Inglês Científico						
			•					

Pharmacy Practice 8



China China Meet at the 2nd largest pharma market REGISTER NOW

-21 June 2023 | Shanghai, China

SCOPE


Pharmacy Practice is a free full-text peer-reviewed journal with a scope on pharmacy practice. Pharmacy Practice is published quarterly. Pharmacy Practice does not charge and will never charge any publication fee or article processing charge (APC) to the authors. The current and future absence of any article processing charges (APCs) is signed in the MoU with the Center for Pharmacy Practice Innovation (CPPI) at Virginia Commonwealth University (VCU) School of Pharmacy. Pharmacy Practice is the consequence of the efforts of a number of colleagues from different Universities who belief in collaborative publishing: no one pays, no one receives. Although focusing on the practice of pharmacy. Pharmacy Practice covers a wide range of pharmacy activities, among them and not being comprehensive, clinical pharmacy, pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology, etc.

 \bigcirc Join the conversation about this journal



Submit paper for publication

^



() ×

Submit paper for publication

